Literature DB >> 31425167

Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated With Worse Prognosis in Patients With Conjunctival Melanoma: Implications for Future AJCC Classifications.

Bita Esmaeli1, Maria Laura Rubin2, Shiqiong Xu1,3, Ryan P Goepfert4, Jonathan L Curry5, Victor G Prieto5, Jing Ning2, Michael T Tetzlaff5.   

Abstract

Identifying tumor characteristics that correlate with metastasis and survival in patients with conjunctival melanoma can potentially lead to better outcomes through a better selection of patients for adjuvant treatments including potentially life-saving new melanoma therapy. The objective of this study was to validate the conjunctival melanoma staging criteria in the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (8th edition) and explore the prognostic importance of tumor thickness, histologic ulceration, and sentinel lymph node biopsy (SLNB) findings in patients with conjunctival melanoma. This is a case series of 88 consecutive patients with conjunctival melanoma. Clinicopathologic characteristics were analyzed. Associations between pathologic characteristics and outcomes were studied using Kaplan-Meier survival analysis. Local recurrence, lymph node metastasis, distant metastasis, and disease-specific survival (DSS) were the main outcome measures. The study included 56 women and 32 men; the median age was 62 years. At presentation, 41 patients had T1 disease, 23 had T2 disease, 23 had T3, and 1 had T4 disease. Sixty-six patients had invasive conjunctival melanoma (median thickness, 1.56 mm), 17 had conjunctival melanoma in situ, and in 5 patients, tumor thickness could not be determined. Overall, 22 patients had ulceration. In total, 31 patients underwent SLNB, and 4 had a positive sentinel lymph node (SLN). The median follow-up time was 46.6 months. Overall, 12 patients had nodal metastasis at presentation or during follow-up, 19 patients had distant metastasis at last follow-up, and 14 patients died of the disease. Tumor thickness and ulceration were associated with increased risks of nodal metastasis, distant metastasis, and death from the disease. Overall, greater clinical T category at presentation was associated with increased risks of distant metastasis and disease-related death; however, the risks of distant metastasis and disease-related death did not differ between T1 (bulbar) and T2 (nonbulbar) tumors or between T2c,d (caruncular) and T1-T2a,b (noncaruncular) tumors. In patients who underwent SLNB, a positive SLN was associated with worse distant metastasis free survival and DSS. Consideration should be given to adding ulceration and emphasizing tumor thickness as the main determinants of pathologic T category for conjunctival melanoma in future AJCC classifications. The significant association between a positive SLN and worse DSS highlights the importance of SLNB for prognosis in patients with conjunctival melanoma and selecting high-risk patients for adjuvant drug treatment.

Entities:  

Mesh:

Year:  2019        PMID: 31425167     DOI: 10.1097/PAS.0000000000001344

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management.

Authors:  Zaoqu Liu; Hui Xu; Siyuan Weng; Chunguang Guo; Qin Dang; Yuyuan Zhang; Yuqing Ren; Long Liu; Libo Wang; Xiaoyong Ge; Zhe Xing; Jian Zhang; Peng Luo; Xinwei Han
Journal:  Cancer Immunol Immunother       Date:  2022-08-23       Impact factor: 6.630

2.  Epidermal Growth Factor Is Increased in Conjunctival Malignant Melanoma.

Authors:  Vinodh Kakkassery; Christoph Wirtz; Marc Schargus; Salvatore Grisanti; Aysegül Tura; Mahdy Ranjbar; H Burkhard Dick; Sabrina Reinehr; Stephanie C Joachim
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

3.  Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma.

Authors:  Bennett Yau-Bun Hong; Joshua R Ford; Isabella C Glitza; Carlos A Torres Cabala; Michael Tetzlaff; Victor G Prieto; Richard Parker; Claire Daniel; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2021 Jan-Feb 01       Impact factor: 2.011

Review 4.  Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know.

Authors:  Kalijn Fredrike Bol; Marco Donia; Steffen Heegaard; Jens Folke Kiilgaard; Inge Marie Svane
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

Review 5.  Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing.

Authors:  Natasha M van Poppelen; Daniël P de Bruyn; Tolga Bicer; Rob Verdijk; Nicole Naus; Hanneke Mensink; Dion Paridaens; Annelies de Klein; Erwin Brosens; Emine Kiliҫ
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

6.  Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature.

Authors:  Barbara Peric; Spela Leiler; Gregor Hawlina; Boris Jancar; Marko Snoj; Andraz Perhavec
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  Clinicopathologic features and survival outcomes of ocular melanoma: a series of 31 cases from a tertiary university hospital.

Authors:  Selin Kestel; Feriha Pınar Uyar Göçün; Betül Öğüt; Özlem Erdem
Journal:  J Pathol Transl Med       Date:  2022-05-03

8.  Publication trends of research on conjunctival melanoma during 1997-2022: A 25-year bibliometric study.

Authors:  Wei Xu; Ludi Yang; Shengfang Ge; Shichong Jia; Fen Gu
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

Review 9.  Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.

Authors:  Ho-Seok Sa; Claire Daniel; Bita Esmaeli
Journal:  J Ophthalmic Vis Res       Date:  2022-08-15

10.  TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models.

Authors:  Quanchi Chen; Vadde Ramu; Yasmin Aydar; Arwin Groenewoud; Xue-Quan Zhou; Martine J Jager; Houston Cole; Colin G Cameron; Sherri A McFarland; Sylvestre Bonnet; B Ewa Snaar-Jagalska
Journal:  Cancers (Basel)       Date:  2020-03-04       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.